scholarly journals Studi Kasus Pada Ibu Hamil Ny K Dengan Jarak Kehamilan Dekat Dan Anemia

2021 ◽  
Vol 1 ◽  
pp. 1925-1929
Author(s):  
Hasri Zaemah Holimah ◽  
Risqi Dewi Aisyah
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Design Method ◽  
Deficiency Anemia ◽  
Severe Anemia ◽  
Premature Labor ◽  
Midwifery Care ◽  
Examination Method ◽  
In Pregnancy

AbstractAnemia is defined as a condition with Hb levels in the blood below the normal 11gr/dL, anemia in Indonesia that often occurs is iron deficiency anemia. According to WHO that pregnant women who experience iron deficiency are around 35-37% and will increase with gestational age, iron deficiency anemia in pregnant women has a bad impact on both the mother and the fetus. Pregnant women with severe anemia are more likely to have premature labor and have low birth weight (LBW) babies and increase perinatal mortality. The design method used in this case describes midwifery care in pregnant women with anemia. Data was collected by anamnesis physical examination method, through inspection, palpation, auscultation, percussion. For this reason, midwives are expected to provide care to overcome anemia in pregnancy so that it does not cause ongoing problemsKeywords: Anemia; Pregnancy AbstrakAnemia didefinisikan sebagai kondisi dengan kadar Hb dalam darah di bawah normal 11gr/dL, anemia di indonesia yang sering terjadi adalah anemia defisiensi zat besi. Menurut WHO bahwa ibu hamil yang mengalami defisiensi besi sekitar 35-37% dan akan semakin meningkat seiring dengan usia kehamilan, anemia defisiensi zat besi pada ibu hamil mempunyai dampak buruk baik pada ibunya maupun pada janin yang dikandungnya. ibu hamil dengan anemia berat lebih memungkinkan terjadinya partus premature dan memiliki bayi berat badan lahir rendah (BBLR) serta meningkatkan kematian perinatal. Rancangan metode yang dilakukan pada kasus ini menggambarkan asuhan kebidanan pada kehamilan dengan anemia. Pengumpulan data dilakukan dengan metode anamnesa pemeriksaan fisik, melalui inspeksi, palpasi, auskltasi, perkusi. Untuk itu bidan di harapkan dapat memberikan asuhan untuk mengatasi anemia pada kehamilan sehingga tidak menimbulkan masalah yang berkelanjutanKata kunci: Anemia;Kehamilan

scholarly journals Treatment of Anemia of Chronic Disease with True Iron Deficiency in Pregnancy

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Gabriela Amstad Bencaiova ◽  
Alexander Krafft ◽  
Roland Zimmermann ◽  
Tilo Burkhardt
Keyword(s):  
Chronic Disease ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Deficiency Anemia ◽  
Anemia Of Chronic Disease ◽  
Human Erythropoietin ◽  
Anemia Treatment ◽  
In Pregnancy

Objective.We assess and compare the efficacy of anemia treatment in pregnant women with anemia of chronic disease with true iron deficiency and in women with iron deficiency anemia.Study Design.Fifty patients with moderate anemia (hemoglobin 8.0–9.9 g/dl) and iron deficiency (ferritin < 15 μg/l) were treated in the Anemia Clinic at the Department of Obstetrics.Results.All patients showed stimulation of erythropoiesis as evidenced by an increase in reticulocyte count at day eight of therapy and showed an increase in hemoglobin and hematocrit at the end of therapy (p<0.001). The target hemoglobin (≥10.5 g/dl) was achieved in 45/50 women (90%). 12 patients showed anemia of chronic disease with true iron deficiency (12/50; 24%). Seven women (7/12; 59%) with anemia of chronic disease and iron deficiency responded well to anemia treatment. 50% of women with anemia of chronic disease and iron deficiency (3/6) responded well to intravenous iron, and 67% (4/6) responded well to the combination of intravenous iron and recombinant human erythropoietin.Conclusion.Because of frequent true iron deficiency in pregnant women with anemia of chronic disease, anemia of chronic disease in pregnancy is often falsely diagnosed as iron deficiency anemia.

scholarly journals REGAIN STUDY: Retrospective Study to Assess the Effectiveness, Tolerability, and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnant Women

Anemia ◽  
2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Saleema Wani ◽  
Mariyam Noushad ◽  
Shabana Ashiq
Keyword(s):  
Retrospective Study ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Oral Iron ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
Blood Hemoglobin ◽  
Iv Iron ◽  
In Pregnancy

Iron deficiency anemia (IDA) during pregnancy arises because of preexisting inadequate stores or complex physiological changes and can lead to serious maternal and fetal complications. Oral iron, either as iron sulfate or fumarate, with or without folic acid, is the most commonly used treatment for IDA in pregnancy. Intravenous (IV) iron has a role in the treatment of IDA in pregnancy, particularly in women who present late, display severe anemia (Hb ≤ 9 g/dL), or risk factors, and are intolerant/noncompliant of oral iron. Previously, administration of IV iron was minimal, owing to potentially serious anaphylactic reactions. Recently, new IV iron products have been developed, offering better compliance, tolerability, efficacy, and a good safety profile. Our study aimed to assess the effectiveness, safety, and tolerability of IV ferric carboxymaltose (FCM) in the treatment of IDA in pregnant women in the UAE. Data from 1001 pregnant women who received at least one administration of FCM (500, 1000, or 1500 mg) during their second or third trimester of pregnancy (2 years backward from study initiation) were collected retrospectively from electronic medical records at Corniche Hospital, Abu Dhabi, UAE. Results showed that 41.4% of the women were able to achieve an increase of ≥2 g/dL in blood hemoglobin overall. A change of ≥2 g/dL was achieved by 27.5% of women administered a dose of 500 mg, 39.2% of women administered a dose of 1000 mg, and 63.9% of women administered a dose of 1500 mg of IV FCM. This indicates a directly proportional relationship between increasing IV FCM dose and the increase of ≥2 g/dL in blood hemoglobin. A total of 7 (0.7%) women reported mild, nonserious adverse events during the study. Within the limits of this retrospective study, IV FCM therapy was safe and effective in increasing the mean hemoglobin of pregnant women with IDA.

scholarly journals Perspectives of Pregnant Women Regarding Iron Deficiency Anemia

Jurnal NERS ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. 119
Author(s):  
Sirikanok Klankhajhon ◽  
Kornkarn Pansuwan ◽  
Kanokon Klayjan ◽  
Nannaphat Nensat
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Perinatal Death ◽  
Qualitative Interviews ◽  
Normal Pregnancy ◽  
Deficiency Anemia ◽  
Care Clinic ◽  
Maternal Instinct ◽  
In Pregnancy

Introduction: Iron deficiency anemia (IDA) is a global health problem. The prevalence of anemia in pregnancy worldwide is nearly half of pregnant women. It impacts on women and offspring outcomes during pregnancy, intrapartum and postpartum period associated with increasing rate of preterm labor, pregnancy induced hypertension, low birth weight, perinatal death including postpartum hemorrhage, postpartum infection, unsuccessful rate of exclusive breast feeding, and postpartum depression. Inadequate iron intake, maternal physiological changes during pregnancy, and bleeding were indicated as common causes of IDA in pregnancy. The objective was to explore the experiences of pregnant women regarding IDA.Methods: A total of eighteen women between 16-36 weeks gestation participated in the qualitative research. Women were selected by purposive sampling according to inclusion criteria to in-depth interviewed at antenatal care clinic, Watbot hospital, Phitsanulok, Thailand.Results: Thematic analysis of the qualitative interviews identified four main themes: iron-deficiency anemia in pregnant as a normal pregnancy; concern on food rather than hematocrit (Hct) level; maternal instinct in healthy baby; and low socioeconomic as a main obstacle.  Conclusion: The findings illustrated to enhance better understanding the nature, attitude, knowledge, perception, and behavior of pregnant women on IDA, facilitators to support women for healthy behavior, and barriers to IDA in pregnancy based on Thai context.

Erythroid Growth Differentiation Factor 15 and Ferroportin Expression During Gestational Iron Deficiency Anemia

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 5286-5286
Author(s):  
Rekha Athiyarath ◽  
Kalaiselvi Sakthivel ◽  
Vinod J Abraham ◽  
Daisy Singh ◽  
Alok Srivastava ◽  
...  
Keyword(s):  
Gene Expression ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Iron Homeostasis ◽  
Iron Absorption ◽  
Deficiency Anemia ◽  
Protein Levels ◽  
In Pregnancy

Abstract Abstract 5286 Iron homeostasis during pregnancy is modulated to meet the increased iron needs but how this is achieved is not very clear. Growth Differentiation Factor (GDF15) produced by the expanded erythroid compartment in β thalassemia has been shown to increase iron absorption by suppressing hepcidin. GDF15 is also highly expressed in the placenta and increasing levels of GDF15 are seen with advancing gestational age of pregnancy. But the role of GDF15 in iron homeostasis in pregnancy has not been elucidated till date. Ferroportin (FPN) is the only known protein involved in iron export and it is the target of hepcidin, the central regulator of iron homeostasis. In this study we analyzed the expression of GDF15 and FPN in pregnant women with iron deficiency anemia. Fourteen pregnant women with proven iron deficiency anemia (IDAP) [Hb<11g/dL and Ferritin <12ng/ul] and thirteen healthy subjects as controls (NC) were enrolled as part of an ongoing study. Serum GDF15 and hepcidin levels were measured by ELISA kits from R&D systems and Bachem, UK respectively. Reticulocytes were isolated and total RNA was purified using Trizol. GDF15 and FPN transcripts were quantified using Taqman Gene expression assays using GAPDH as an internal control. Gene expression values were calculated on the basis of the 2-ΔΔCt method. The mean age of the pregnant women was 22.5±2.5 years. The median ferritin in IDAP was 1.4 and ranged from 0.2 to 8.3 ng/ml. The hepcidin levels were very low [<2ng/ml] in IDAP. Serum GDF15 levels in IDAP was significantly higher as compared to controls [IDAP-3333.71±409 pg/ml vs. NC-309.7±127.0 pg/ml; p=0.000]. Reticulocyte GDF15 mRNA expression was significantly lower [IDAP-25.09 (1.28–239.8) vs. NC-910.4 (0.28–1962); p=0.004] and FPN expression was significantly higher in pregnancy [IDAP-209.8 (48.33–1201) vs. NC-77.96(17.21–281.3); p=0.001] than in the controls. GDF15 mRNA as well as serum GDF15 levels significantly correlated with FPN expression in IDAP [RNA r=0.895; p=0.000; Protein r=0.555, p=0.049] Eight patients were followed up after 8 weeks of supplementation and there was no significant change in the serum GDF15 concentration (3235±468.26pg/ml; p=1.000). However their serum ferritin and hepcidin levels were significantly higher [Ferritin-11.60 (9.80–21.30), p=0.0021; Hepcidin-17.86(0.29–38.50), p=0.015]. There was no significant correlation between GDF15 protein levels and hepcidin (r=0.429, p=0.354). Molecular mechanisms of iron homeostasis in pregnancy are poorly understood. IDAP had very low hepcidin levels which normalized after iron stores were replenished. Elevated GDF15 protein levels in IDAP inspite of low reticulocyte expression indicate that erythroid contribution is minimal and placenta is the main source of GDF15. The significant correlation between GDF15 (mRNA and protein) with FPN expression and absence of correlation with hepcidin levels indicate a possible role for GDF15 in iron homeostasis in pregnancy. These findings has to be validated and the role of GDF15 in modulating FPN and there by iron absorption has to be further elucidated. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Iron Deficiency Anemia in Pregnancy: Can We eradicate?

2017 ◽  
Vol 1 (2) ◽  
pp. 36-39
Author(s):  
Sujal Munshi ◽  
Atul Munshi
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Correct Answer ◽  
Common Type ◽  
Deficiency Anemia ◽  
Root Cause ◽  
Severe Deficiency ◽  
Anemia In Pregnancy ◽  
In Pregnancy

ABSTRACT Iron deficiency anemia (IDA) is the most common type of anemia. Most of the anemic patients, especially women, suffer from mild to severe deficiency of iron. Almost 50% of all pregnant women experience IDA during their pregnancies, and at least 1 out of 5 of girls and women may experience it during their reproductive years. One complete eradication of IDA is not feasible but a try can help us on a long way. Only supplementation is not the answer. Going to the root cause, finding out current situation and managing accordingly by available resources is the correct answer. How to cite this article Munshi A, Munshi S. Iron Deficiency Anemia in Pregnancy: Can We eradicate? World J Anemia 2017;1(2):36-39.

scholarly journals Three-Month Iron Supplementation as Treatment for Microcytic Hypochromic Anemia in Pregnancy

2021 ◽  
Vol 53 (2) ◽  
Author(s):  
Donel Donel ◽  
Dhini Aiyulie Novri ◽  
Ruza Prima Rustam ◽  
Maya Savira
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anemia ◽  
Iron Supplementation ◽  
Hypochromic Anemia ◽  
Primary Data ◽  
Deficiency Anemia ◽  
Quasi Experimental ◽  
Anemia In Pregnancy ◽  
In Pregnancy

In pregnant women there is a twofold increase in iron requirements due to increased blood volume without the expansion of plasma volume. Pregnant women are very prone to suffering from iron deficiency anemia. Iron deficiency anemia generally has an erythrocyte index which represents hypochromic microcytic. This study aimed to determine the effect of three-month iron tablet supplementation as a therapy against microcytic hypochromic anemia in pregnancy. This was a quantitative quasi-experimental study using pre-test and post-test design. The study was conducted in May-September 2020 at the Arifin Achmad Regional General Hospital, Riau Province, Indonesia. Subjects were 30 pregnant women with microcytic hypochromic anemia. Primary data were analyzed using statistical paired sample t-tests. Results showed that there was an increase in hemoglobin levels after the supplementation of iron tablet from an average of 9.1 ± 1.2 gr/dl to 11.8 ± 1.0 g/dl. This change was significant based on the results of the T-test (p-0.003) Thus, iron supplementation for three month significantly increases hemoglobin levels in pregnant women.

Sign in / Sign up

Export Citation Format

Share Document